Mremi Alex, Chipongo Hilary, Urassa Ellyagape, Mkwizu Elifuraha, Lodhia Jay
Department of Pathology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Faculty of Medicine, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Clin Pathol. 2024 Sep 6;17:2632010X241276947. doi: 10.1177/2632010X241276947. eCollection 2024 Jan-Dec.
Primary breast lymphoma (PBL) is a rare malignant lymphoid neoplasm limited to the breast, accounting for about 0.15% of all malignant breast tumors and 1.7% to 2.2% of extra-nodal lymphomas. PBL must be distinguished from conventional breast carcinomas due to different therapeutic approaches. A 25-year-old female presented with a left breast mass. Histopathology and immunohistochemical tests confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL). She had no similar lesions elsewhere in the body. She received 1 cycle of R-CHOP chemotherapy but absconded from the treatment and succumbed afterward while at home. Recent developments in DLBCL treatment have greatly improved patient outcomes by incorporating targeted medicines like rituximab, increased chemotherapy regimens, new drugs, and individualized treatment techniques. PBL appears to have a worse prognosis; thus, delay or abscondment from treatment is of serious concern when it comes to improving the prognosis of patients with PBL.
原发性乳腺淋巴瘤(PBL)是一种罕见的恶性淋巴肿瘤,局限于乳腺,约占所有恶性乳腺肿瘤的0.15%,占结外淋巴瘤的1.7%至2.2%。由于治疗方法不同,PBL必须与传统乳腺癌相区分。一名25岁女性因左乳肿块就诊。组织病理学和免疫组化检查确诊为弥漫性大B细胞淋巴瘤(DLBCL)。她身体其他部位无类似病变。她接受了1个周期的R-CHOP化疗,但中途放弃治疗,随后在家中死亡。通过纳入利妥昔单抗等靶向药物、增加化疗方案、使用新药以及采用个体化治疗技术,DLBCL治疗的最新进展极大地改善了患者的预后。PBL的预后似乎更差;因此,对于改善PBL患者的预后而言,治疗延误或放弃治疗是严重问题。